NIH: Begins Clinical Trial of Antiviral Remdesivir and Baricitinib (Anti-Inflammatory) For COVID-19

3
2365

Health Editor’s Note: COVID-19 is likely to respond to a cocktail of antivirals and anti-inflammatory drugs. The antiviral, Remdesivir has been shown to decrease recovery time in patients with COVID-19.  The drug chosen to be used with Remdesivir is Baricitinib (Olumiant) which is a proven anti-inflammatory drug, currently approved in the U.S. and 65 other countries for patients with rheumatoid arthritis.  People with rheumatoid arthritis have cytokine storms which cause issues with hyper-inflammatory responses with their joints as opposed to hyper-inflammatory reactions in the lungs of patients with COVID-19. It is hoped that the addition of an anti-inflammatory will keep the lungs healthier and able to repair themselves and will decrease the chances of getting ARDS which is associated with COVID-19 deaths……Carol  

NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins

NIH News Release:

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019 (COVID-19) has begun. The trial is now enrolling hospitalized adults with COVID-19 in the United States. The trial is expected to open at approximately 100 U.S. and international sites. Investigators currently anticipate enrolling more than 1,000 participants. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial.



The clinical trial is the next iteration of NIAID’s Adaptive COVID-19 Treatment Trial (ACTT), which began on Feb. 21 to evaluate remdesivir, an investigational broad-spectrum antiviral treatment developed by Gilead Sciences, Inc. That trial closed to enrollment on April 19 after recruiting 1,063 participants at 47 U.S. and 21 international sites. An independent data and safety monitoring board (DSMB) overseeing the trial met on April 27 and shared their preliminary analysis with the study sponsor, NIAID. Their analysis showed that patients who received remdesivir had a statistically significant shorter time to recovery compared to patients who received placebo. More detailed information about the trial results, including more comprehensive data, will be available in a forthcoming report. In this next trial with baricitinib, called ACTT 2, all participants will receive remdesivir or remdesivir with baricitinib.

“We now have solid data showing that remdesivir diminishes to a modest degree the time to recovery for people hospitalized with COVID-19,” said NIAID Director Anthony S. Fauci, M.D. “ACTT 2 will examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients, including improving mortality outcomes.”

Baricitinib(link is external), a product licensed to Eli Lilly and Company by Incyte and marketed under the brand name Olumiant, is approved in the U.S. and in more than 65 additional countries as a treatment for adults with moderately to severely active rheumatoid arthritis. Read More:

ATTENTION READERS

We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.

3 COMMENTS

  1. Excuse me… let me first say Happy Mothers Day! I don’t mean to string on my comment but I was not complete in my thought. There are now signs of transference of some of the COVID-19 in sperm which is another thing that sets this virus apart from Influenza. And I have been reading some studies that seem to be coming from microbiologists and virologist showing similarities of HIV to how the ‘viron’? fools the host cell into accepting it across the membrane. They use this example to show how this COVID-19 virus is likely to be a product of a lab and not a straight up bat-to-human natural mutation.

  2. This is sounding a lot more like HIV/AIDS tx.? Are we getting any more indications that a vaccine will not be effective or lasting?

    • SouthThunder230, As far as probably needing a cocktail of different types of drugs to treat it, it is very much like HIV/AIDS. Of course the method of transference is far different. It is impossible to control a virus that spreads by air with such abandonment. Not sure of the vaccines and if it will be effective….many studies are ongoing. I am sure that the end result is to seek a permanent/effective vaccine when all the testing is over. We can only hope that we get success…. Carol

Comments are closed.